|
[1]
|
Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Abete, P., Della-Morte, D., Gargiulo, G., et al. (2014) Cognitive Impairment and Cardiovascular Diseases in the Elderly. A Heart-Brain Continuum Hypothesis. Ageing Research Reviews, 18, 41-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Robinson, J.G. and Stone, N.J. (2015) The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk: A New Paradigm Supported by More Evidence. European Heart Journal, 36, 2110-2118. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Holmes, M.V., Richardson, T.G., Ference, B.A., et al. (2021) Integrating Genomics with Biomarkers and Therapeutic Targets to Invigorate Cardiovascular Drug Development. Nature Reviews Cardiology, 18, 435-453. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Reiner, Ž. (2013) Statins in the Primary Prevention of Cardiovascular Disease. Nature Reviews Cardiology, 10, 453-464. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Piepoli, M.F., Hoes, A.W., Agewall, S., et al. (2016) 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited Experts): Developed with the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Journal of Preventive Cardiology, 23, Np1-Np96. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Mihaylova, B., Emberson, J., Blackwell, L., et al. (2012) The Effects of Lowering LDL Cholesterol with Statin Therapy in People at Low Risk of Vascular Disease: Meta-Analysis of Individual Data from 27 Randomised Trials. The Lancet, 380, 581-590. [Google Scholar] [CrossRef]
|
|
[8]
|
O’Donoghue, M.L., Giugliano, R.P., Wiviott, S.D., et al. (2022) Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. Circulation, 146, 1109-1119. [Google Scholar] [CrossRef]
|
|
[9]
|
Nissen, S.E., Lincoff, A.M., Brennan, D., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England Journal of Medicine, 388, 1353-1364. [Google Scholar] [CrossRef]
|
|
[10]
|
Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine, 372, 2387-2397. [Google Scholar] [CrossRef]
|
|
[11]
|
Padala, K.P., Padala, P.R. and Potter, J.F. (2006) Simvastatin-Induced Decline in Cognition. Annals of Pharmacotherapy, 40, 1880-1883. [Google Scholar] [CrossRef]
|
|
[12]
|
King, D.S., Wilburn, A.J., Wofford, M.R., et al. (2003) Cognitive Impairment Associated with Atorvastatin and Simvastatin. Pharmacotherapy, 23, 1663-1667. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Khan, A.R., Bavishi, C., Riaz, H., et al. (2017) Increased Risk of Adverse Neurocognitive Outcomes with Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors. Circulation: Cardiovascular Quality and Outcomes, 10, e003153. [Google Scholar] [CrossRef]
|
|
[14]
|
Sirtori, C.R. (2014) The Pharmacology of Statins. Pharmacological Research, 88, 3-11. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Adhyaru, B.B. and Jacobson, T.A. (2018) Safety and Efficacy of Statin Therapy. Nature Reviews Cardiology, 15, 757-769. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Ward, N.C., Watts, G.F. and Eckel, R.H. (2019) Statin Toxicity. Circulation Research, 124, 328-350. [Google Scholar] [CrossRef]
|
|
[17]
|
Ference, B.A., Majeed, F., Penumetcha, R., et al. (2015) Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or both: A 2 × 2 Factorial Mendelian Randomization Study. Journal of the American College of Cardiology, 65, 1552-1561. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Garcia-Calvo, M., Lisnock, J., Bull, H.G., et al. (2005) The Target of Ezetimibe Is Niemann-Pick C1-Like 1 (NPC1L1). Proceedings of the National Academy of Sciences of the United States of America, 102, 8132-8137. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. (2015) Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. The New England Journal of Medicine, 372, 1500-1509. [Google Scholar] [CrossRef]
|
|
[20]
|
Stein, E.A. and Swergold, G.D. (2013) Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics. Current Atherosclerosis Reports, 15, Article No. 310. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Blom, D.J., Hala, T., Bolognese, M., et al. (2014) A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. The New England Journal of Medicine, 370, 1809-1819. [Google Scholar] [CrossRef]
|
|
[22]
|
Barter, P.J. and Rye, K.A. (2006) Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, 113, 1553-1555. [Google Scholar] [CrossRef]
|
|
[23]
|
Jacobson, T.A. (2009) Myopathy with Statin-Fibrate Combination Therapy: Clinical Considerations. Nature Reviews Endocrinology, 5, 507-518. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Rojas-Fernandez, C.H., Goldstein, L.B., Levey, A.I., et al. (2014) An Assessment by the Statin Cognitive Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S5-S16. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Diamond, A. (2013) Executive Functions. Annual Review of Psychology, 64, 135-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hickok, G. and Poeppel, D. (2007) The Cortical Organization of Speech Processing. Nature Reviews Neuroscience, 8, 393-402. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Milner, A.D. and Goodale, M.A. (2008) Two Visual Systems Re-Viewed. Neuropsychologia, 46, 774-785. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Ong, K.L., Morris, M.J., McClelland, R.L., et al. (2018) Relationship of Lipids and Lipid-Lowering Medications with Cognitive Function: The Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 187, 767-776. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Samaras, K., Makkar, S.R., Crawford, J.D., et al. (2019) Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly. Journal of the American College of Cardiology, 74, 2554-2568. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Kemp, E.C., Ebner, M.K., Ramanan, S., et al. (2020) Statin Use and Risk of Cognitive Decline in the ADNI Cohort. The American Journal of Geriatric Psychiatry, 28, 507-517. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Zeki Al Hazzouri, A., Jawadekar, N., Grasset, L., et al. (2022) Statins and Cognitive Decline in the Cardiovascular Health Study: A Comparison of Different Analytical Approaches. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 77, 994-1001. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Eden Friedman, Y., Steinberg, D.M., Canetti, M., et al. (2021) An Impact of Lipid Profile and Lipid Lowering Drugs on ≥ 70 Year Olds of an Upper Socioeconomic Class: A Retrospective Cohort Study. Lipids in Health and Disease, 20, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Ott, B.R., Daiello, L.A., Dahabreh, I.J., et al. (2015) Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of General Internal Medicine, 30, 348-358. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Shepherd, J., Blauw, G.J., Murphy, M.B., et al. (2002) Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomised Controlled Trial. The Lancet, 360, 1623-1630. [Google Scholar] [CrossRef]
|
|
[35]
|
(2002) MRC/BHF Heart Protection Study of Antioxidant Vitamin Supplementation in 20,536 High-Risk Individuals: A Randomised Placebo-Controlled Trial. The Lancet, 360, 23-33. [Google Scholar] [CrossRef]
|
|
[36]
|
Harvey, P.D., Sabbagh, M.N., Harrison, J.E., et al. (2018) No Evidence of Neurocognitive Adverse Events Associated with Alirocumab Treatment in 3340 Patients from 14 Randomized Phase 2 and 3 Controlled Trials: A Meta-Analysis of Individual Patient Data. European Heart Journal, 39, 374-381. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Giugliano, R.P., Mach, F., Zavitz, K., et al. (2017) Cognitive Function in a Randomized Trial of Evolocumab. The New England Journal of Medicine, 377, 633-643. [Google Scholar] [CrossRef]
|
|
[38]
|
Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine, 376, 1713-1722. [Google Scholar] [CrossRef]
|
|
[39]
|
Schwartz, G.G., Steg, P.G., Szarek, M., et al. (2018) Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine, 379, 2097-2107. [Google Scholar] [CrossRef]
|
|
[40]
|
Guedeney, P., Giustino, G., Sorrentino, S., et al. (2022) Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. European Heart Journal, 43, E17-E25. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Giugliano, R.P., Mach, F., Zavitz, K., et al. (2017) Design and Rationale of the EBBINGHAUS Trial: A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid-Lowering Therapy—A Cognitive Study of Patients Enrolled in the FOURIER Trial. Clinical Cardiology, 40, 59-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Mannarino, M.R., Sahebkar, A., Bianconi, V., et al. (2018) PCSK9 and Neurocognitive Function: Should It Be Still an Issue after FOURIER and EBBINGHAUS Results? Journal of Clinical Lipidology, 12, 1123-1132. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lohoff, F.W. (2018) Lipid-Lowering Drug Effects beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders. International Journal of Neuropsychopharmacology, 21, 1076-1078. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
O’Connell, E.M. and Lohoff, F.W. (2020) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. Frontiers in Neuroscience, 14, Article No. 609. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Ballantyne, C.M., Houri, J., Notarbartolo, A., et al. (2003) Effect of Ezetimibe Coadministered with Atorvastatin in 628 Patients with Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial. Circulation, 107, 2409-2415. [Google Scholar] [CrossRef]
|
|
[46]
|
Kim, S.H., Kim, G., Han, D.H., et al. (2017) Ezetimibe Ameliorates Steatohepatitis via AMP Activated Protein Kinase-TFEB-Mediated Activation of Autophagy and NLRP3 Inflammasome Inhibition. Autophagy, 13, 1767-1781. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Bhateja, D.K., Dhull, D.K., Gill, A., et al. (2012) Peroxisome Proliferator-Activated Receptor-α Activation Attenuates 3-Nitropropionic Acid Induced Behavioral and Biochemical Alterations in Rats: Possible Neuroprotective Mechanisms. European Journal of Pharmacology, 674, 33-43. [Google Scholar] [CrossRef] [PubMed]
|